{"id":"NCT00115076","sponsor":"Rockefeller University","briefTitle":"Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis","officialTitle":"A Phase IIIB Study to Evaluate the Mechanism of Action of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-08-04","primaryCompletion":"2009-05-18","completion":"2011-04-06","firstPosted":"2005-06-21","resultsPosted":"2021-02-08","lastUpdate":"2021-02-08"},"enrollment":31,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Efalizumab","otherNames":["Raptiva"]}],"arms":[{"label":"psoriasis","type":"EXPERIMENTAL"}],"summary":"Our laboratory is studying a skin disease known as psoriasis. The purpose of this protocol is to study the action and the effects of Efalizumab, on psoriasis. This medication has been studied extensively and has been found to be effective and safe in the treatment of psoriasis. The eligible patient will have 10% of his/her body surface area involved with psoriasis vulgaris.","primaryOutcome":{"measure":"Number of Participants With Clinical Improvement of Target Lesions","timeFrame":"week 12","effectByArm":[{"arm":"Psoriasis","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["22348003"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Upper Respiratory Infection","fatigue","joint pain","diarrhea","chills"]}}